CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data [Seeking Alpha]
CG Oncology, Inc. (CGON)
Company Research
Source: Seeking Alpha
J&J is developing its asset and CG Oncology is developing cretostimogene for non-muscle invasive bladder cancer. TAR-200 is designed to provide targeted local release of gemcitabine into the bladder. Cretostimogene, which is in phase 3, is an oncolytic immunotherapy designed to replicate in retinoblastoma (Rb) gene pathway-defective cells seen in the majority of urothelial carcinomas and trigger an anti-tumor immune response, according to CG Oncology. Phase 2b data on TAR-200, just presented at the European Society for Medical Oncology Congress, showed that 83.5% of patients in the TAR-200 monotherapy cohort achieved a complete response. In this group, 82% of patients maintained that response after a median follow-up of six months, and an estimated 12-month CR rate of 57.4%. Data from two other cohorts, TAR-200 + the experimental cetrelimab, showed CR rates of, respectively, 67.9% and 46.4%. In a recent note, Cantor's Eric Schmidt, who rates CG Oncology a buy, said that the TAR
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Investors optimistic about continued biotech and medtech IPO resurgence in 2025 [Yahoo! Finance]Yahoo! Finance
- CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
CGON
Earnings
- 11/12/24 - Beat
CGON
Sec Filings
- 2/14/25 - Form SCHEDULE
- 1/28/25 - Form SCHEDULE
- 1/14/25 - Form 4
- CGON's page on the SEC website